Michael C. Milone

Children's Hospital of Philadelphia — United States

Medicine · Health Sciences

56h-index23.2kcitations324works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(211), Immune Cell Function and Interaction(62), Immunotherapy and Immune Responses(51), Viral Infectious Diseases and Gene Expression in Insects(35), Virus-based gene therapy research(28)

Publications322 total

DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity
Molecular Therapy·2025Open Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor
Blood Immunology & Cellular Therapy·2025Open Access
Synkir-310 split-signaling based KIR-CAR T cell therapy achieves faster and deeper anti-B cell tumor efficacy with reduced cytokine levels
Blood·2025
β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming
Blood·2025Open Access
1238 Histopathologic analysis of mesothelin expression in cholangiocarcinoma supports inclusion in biomarker-targeted clinical trials
Regular and Young Investigator Award Abstracts·2025Open Access
298 A novel NK-cell based split-signaling killer immunoglobulin receptor (KIR)-based CAR T targeting mesothelin, SynKIR-110, shows increased safety profile and increased efficacy <i>in vitro</i> and <i>in vivo</i>
Regular and Young Investigator Award Abstracts·2025Open Access
Improved Tumor Specificity of Mesothelin (MSLN)-specific Killer Immunoglobulin Receptor (KIR)-based Chimeric Antigen Receptor (CAR) T cell therapy SynKIR-110 3562
The Journal of Immunology·2025Open Access
0434 Clinical and translational data from a first-in-human study of a novel precision cellular immunotherapy (DSG3-CAART) in mucosal pemphigus vulgaris
Journal of Investigative Dermatology·2025· 1 cited
DR5 CAR-T cells target solid tumors and suppress MDSCs with minimal toxicity
2025Open Access
SynKIR-CAR T cell advanced research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma.
Journal of Clinical Oncology·2025
Clinical advances in gene, cell, and RNA therapies
Molecular Therapy·2025
Concept CARs are picking up speed
Molecular Therapy·2025· 1 cited
Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells
Proceedings of the National Academy of Sciences·2025· 18 citedOpen Access
Performance of a Xylazine Test Strip in Urine Biospecimens
Journal of Addiction Medicine·2025· 1 cited
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis
Cancer Chemotherapy and Pharmacology·2025Open Access
Author Correction: Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells
Nature Biotechnology·2024· 1 citedOpen Access
Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
Blood·2024· 8 citedOpen Access
Abstract 6332: Evaluating the relationship of affinity, functional avidity, and <i>in vivo</i> potency in KIR-CAR T cells
Cancer Research·2024
Therapeutic drug monitoring of selected anticancer drugs
Therapeutic Drug Monitoring·2024
page 1 of 17Next →

Frequent Co-authors

Carl H. June(23), Roddy S. O’Connor(13), Selene Nuñez-Cruz(10), Bruce L. Levine(8), J. Joseph Melenhorst(8), Simon F. Lacey(7), Joseph A. Fraietta(7), James L. Riley(6), John Scholler(6), Stephan A. Grupp(5), Omkar U. Kawalekar(5), Wei‐Ting Hwang(5), Saba Ghassemi(4), Carmine Carpenito(4), Richard G. Carroll(4), Lili Guo(4), Nathaniel W. Snyder(4), Ian A. Blair(4), Steven Μ. Albelda(4), Adam D. Cohen(4)